U.S. markets open in 1 hour 2 minutes

Ampio Pharmaceuticals, Inc. (AMPE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.8400-0.0400 (-2.13%)
At close: 4:00PM EDT
1.8300 -0.01 (-0.54%)
Pre-Market: 08:20AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.8800
Open1.8900
Bid1.8400 x 3000
Ask1.8500 x 3000
Day's Range1.8000 - 1.9200
52 Week Range0.5300 - 2.9800
Volume2,981,989
Avg. Volume1,609,367
Market Cap360.068M
Beta (5Y Monthly)1.83
PE Ratio (TTM)N/A
EPS (TTM)-0.0790
Earnings DateJul 29, 2021 - Aug 02, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index
    PR Newswire

    Ampio Pharmaceuticals, Inc. to Join the Russell 2000® Index and Russell 3000® Index

    ENGLEWOOD, Colo., June 18, 2021 /PRNewswire/ – Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that the Company is expected to join the small cap Russell 2000® Index and the broad-market Russell 3000® Index at the conclusion of this year's reconstitution of the Russell stock indexes, effective after the U.S. stock market opens on Monday, June 28,

  • Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK
    PR Newswire

    Ampio Provides Update on Osteoarthritis of the Knee (OAK) Program, Reiterates Compelling Data in Earlier Phase III Trials of Ampion in Severe OAK

    Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today reported newly integrated data from four of its earlier clinical trials with consistent inclusion, exclusion, and demographic populations utilizing Ampion for treating osteoarthritis of the knee (OAK). Data from these 585 patients categorized as severe (i.e., Kellgren-Lawrence grade 4, or KL 4) demonstrates Ampion's consist

  • Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion
    Benzinga

    Ampio Stock Jumps On Enrollment Expansion Of Mid-Stage COVID-19 Trial To India With Inhaled Ampion

    Ampio Pharmaceuticals Inc (NYSE: AMPE) has received regulatory approval to expand enrollment of its AP-019 Phase 2 study to India, assessing inhaled Ampion to treat those suffering from respiratory distress due to COVID-19. The company said that amid political unrest in Israel and the surrounding region combined with the reduction in COVID cases, it would discontinue the AP-019 study in Israel and instead reallocate the resources to India and other potential select territories outside the U.S.,